Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023467 (acute myeloid leukemia)
 35,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Granulocytic sarcoma is an extramedullary tumor of malignant granulocytic progenitor cells that accompanies, heralds, or signals relapse of acute myelogenous leukemia (AML), or indicates blastic transformation of a chronic myeloproliferative disorder. We describe a case involving the uterine cervix of a 51-year-old woman that led to the diagnosis of AML. Granulocytic sarcoma can occur in the female genital tract and may be the first clinically significant manifestation of a hematologic malignancy. The salient findings in 28 reported cases from 12 different countries are reviewed. Awareness of this lesion is important for all medical personnel involved in the health care of women.
 ...
PMID:Granulocytic sarcoma of the uterine cervix--literature review of granulocytic sarcoma of the female genital tract. 163 33

Immunohistochemical detection of intracellular myeloperoxidase, a major constituent of primary granules of neutrophilic myeloid cells, was determined in paraffin sections of 161 specimens using a rabbit polyclonal antibody to human myeloperoxidase and an indirect immunoperoxidase technique. In normal tissues and in a variety of myeloproliferative disorders, myeloid cells of both neutrophilic and eosinophilic types, at all stages of maturation, exhibited strong cytoplasmic reactivity for myeloperoxidase. Myeloperoxidase was readily detected in myeloblasts and immature myeloid cells of acute myelogenous leukemia, progranulocytic leukemia, monomyelocytic leukemia, erythroleukemia, myeloblastomas, and other hematopoietic disorders. Erythroid precursors, megakaryocytes. other hematopoietic disorders. Erythroid precursors, megakaryocytes, lymphoid cells, mast cells, and plasma cells were nonreactive. Cells of monocytic derivation revealed variable reactivity and were typically weakly positive or nonreactive. In a few specimens, rare histiocytes were reactive, some possibly due to phagocytosed material. Cells comprising the infiltrate of a spectrum of lymphoid malignancies, e.q., lymphoblastic lymphoma or leukemia, chronic lymphocytic leukemia, hairy cell leukemia, non-Hodgkin's lymphomas of T- or B-cell type, and Hodgkin's disease, were nonreactive, as were the non-neoplastic tissues present in these specimens, except for occasional cells of myeloid derivation. Myeloperoxidase was not observed in the neoplastic cells of a wide variety of epithelial tumors and sarcomas, or in the contiguous non-neoplastic tissues. Immunoreactivity for myeloperoxidase was well preserved following fixation in a variety of fixatives, including Zenker's-acetic acid solution (employed for processing bone marrow biopsies), B5 solution, and formalin. Immunohistochemical detection of myeloperoxidase represents a sensitive and highly specific technique for identification of mature and immature myeloid cells in paraffin-embedded tissue.
 ...
PMID:Myeloperoxidase: a specific marker for myeloid cells in paraffin sections. 172 87

We report two cases of refractory anemia with excess of blasts in transformation (RAEB-T) with the translocation (8;21), which is frequent in ANLL but not in myelodysplastic syndromes (MDS). A review of such cases leads us to conclude that myeloproliferative disorders characterized by the t(8;21) may be preceded by an MDS phase.
 ...
PMID:Translocation (8;21) in two cases of refractory anemia with excess of blasts in transformation. 172 55

Because chronic benzene exposure is associated with acute myeloblastic leukemia and other myeloproliferative disorders, we sought to determine whether short-term benzene exposure provides a growth advantage for granulopoietic elements over erythropoietic elements. Groups of male DBA/2J mice were exposed to 0, 10, 30, or 100 ppm benzene (6 h/day for 5 days). One day and 5 days after the benzene exposures, the numbers of the two most primitive erythroid progenitor cells (BFU-E and CFU-E) and the numbers of the most primitive granulocytic progenitor cells (GM-CFU-C) were assessed. Additional groups of mice were given hemolytic doses of phenylhydrazine (PHZ) during the 5 days of benzene exposure, while other groups of mice were given PHZ during the 5 days of recovery from benzene exposure. These experiments were designed to determine the effects of benzene exposure on progenitor cell numbers during periods of markedly heightened erythropoiesis. The results demonstrate that short-term benzene exposure does induce a growth advantage for granulocytic cells in both the bone marrow and spleen of exposed mice. Moreover, a benzene-induced shift toward granulopoiesis is observed even in those mice treated with a powerful erythropoietic stimulus. These effects disappear 5 days after cessation of benzene exposure in the bone marrow but persist in the spleen of mice treated with phenylhydrazine.
 ...
PMID:Short term benzene exposure provides a growth advantage for granulopoietic progenitor cells over erythroid progenitor cells. 207 27

During the past 12 years we studied children with unexplained chronic leukocytosis and other findings suggestive of acute or chronic myeloid leukemia (AML; CML). We used cultures in soft agar of peripheral blood for granulocyte-macrophage colony-forming cell (GM-CFC) analysis. Colonies were counted, examined morphologically and cytochemically and the findings in patients were compared with those in normal children and patients with leukemoid reactions. 2 children with confirmed CML and neurofibromatosis (NF) were similarly evaluated. Additional studies in 1 of them and in his mother who had NF, included establishment of fibroblast and blood cultures from affected skin and tumor, and stimulation of normal bone marrow-derived GM-CFC by these fibroblasts and the conditioned medium (CM) from these cultures. Growth of GM-CFC from blood cultures of CML and AML patients was significantly enhanced in comparison with blood cultures from normal donors, or patients with other myeloproliferative disorders or leukemoid reactions. Enhanced GM-CFC growth-supportive activity was obtained from CML-NF skin and tumor culture CM in comparison with CM from normal fibroblasts. These results indicate the diagnostic value of blood culture GM-CFC in juvenile CML, and its usefulness in differentiating between CML and other disorders involving leukocytosis. They suggest a possible connection between NF foci and the enhanced proliferation of blood GM-CFC in CML.
 ...
PMID:[Blood culture for diagnosing juvenile chronic myeloid leukemia; relationship to neurofibromatosis]. 210 34

Forty-one patients with myeloid malignancies, majority newly diagnosed and previously untreated, were systematically karyotyped between January 1988 and December 1989 using fluorodeoxyuridine (FdU) synchronisation and Giemsa banding techniques. Eighteen patients had acute myeloid leukaemia (AML), 13 had one form or other of a myeloproliferative disorder and 10 fulfilled the clinical and morphological criteria for the myelodysplastic syndrome (MDS). Ten AML patients had cytogenetic abnormalities. All 6 chronic myeloid leukaemia (CML) patients carried the Philadelphia chromosome with 2 having additional abnormal clones. Only four MDS patients showed involvement of either chromosome 5 or 7.
 ...
PMID:Cytogenetic analysis in myeloid malignancies. 213 Jul 41

Transient neonatal myeloproliferative disorders (TMD's) indistinguishable from acute leukaemia by clinical and morphological criteria have been described in neonates with Down's syndrome. To analyse its clinical significance, 10 infants under 1 year of age presenting with Down's syndrome and the morphological picture of acute myelogenous leukaemia were reviewed. 3 of these children had true AML leading to death after 2, 8 and 11 months. In the other 7 children the diagnosis TMD was suggested as spontaneous or in one case interferon-induced remission occurred within 4 to 25 weeks after diagnosis. The interferon-treated patient died of SIDS at the age of 11 months. Another one of the TMD children developed fatal erythroleukaemia at the age of 2 years. Regarding initial clinical and haematological parameters, TMD was indistinguishable from true congenital leukaemie. In all patients classification according to the FAB criteria was difficult, as mainly undifferentiated or poorly differentiated myeloid blasts were seen, sometimes with erythro- or megakaryocytic features. Because of the difficulties in the differential diagnosis of TMD and true AML it is recommended to delay specific cytostatic therapy in neonates with Down's syndrome, until definite progression of the leukaemic process is observed or cytogenetic analyses suggesting true AML are available.
 ...
PMID:[Transient myeloproliferation and acute myeloid leukemia in infants with Down's syndrome]. 214 25

Trisomy 21 as an acquired clonal chromosome change has been described in 642 of the 10,625 human neoplasms with chromosome aberrations known from the cytogenetic literature. A total of 590 of the 642 cases (92%) are hematologic disorders and malignant lymphomas. The incidence of trisomy 21 is similar (4.1%-6.7%) in acute myeloid leukemia (AML), chronic myeloid leukemia, myeloproliferative disorders, myelodysplastic syndromes, chronic lymphoproliferative disorders, and malignant lymphomas; it is substantially higher (14.8%) in acute lymphocytic leukemia (ALL). In most cases, the extra chromosome 21 is present together with other numerical and/or structural changes. Acquired trisomy 21 is the only karyotypic abnormality in only 0.4%. Trisomy 21 has never been reported as the sole anomaly in a solid tumor. The cytogenetic literature contains information on 62 patients with constitutional trisomy 21 and a malignant disorder in which the tumor cells have been analyzed by banding techniques. Thirty-four of the 62 patients had AML, 16 had ALL, and 2 had acute undifferentiated leukemia. The 52 leukemic Down syndrome (DS) cases account for 1.4% of the total acute leukemias, an overrepresentation that parallels the generally increased risk of leukemia development in DS. Sixty-three percent of the ALL patients and 79% of those with AML had additional changes superimposed on constitutional trisomy 21. These included several of the characteristic primary leukemia-associated aberrations: 5q-, 7q-, +8, and t(8;21) in AML, and t(1;19), t(4;11), 6q-, and 14q + in ALL. Thus, it seems that the pattern of acquired karyotypic changes is similar in patients with DS and in individuals with a normal constitutional karyotype.
 ...
PMID:Trisomy 21 in neoplastic cells. 214 59

An enzyme-linked immunosorbent assay using specific monoclonal antibodies was used to measure circulating transferrin receptor (TR) in 87 patients with various hematologic malignancies. The mean serum TR was significantly elevated in patients with myeloproliferative disorders (15.47 +/- 12.54 micrograms/ml), whereas there were no differences in chronic granulocytic leukemia (7.89 +/- 3.56 micrograms/ml), myelodysplastic disorders (9.25 +/- 4.73 micrograms/ml), and acute nonlymphocytic leukemia (3.85 +/- 3.50 micrograms/ml) as compared to normal (5.63 +/- 1.42 micrograms/ml). Among patients with lymphoproliferative disorders, the mean level was normal in lymphoma (5.73 +/- 2.59 micrograms/ml), multiple myeloma (5.47 +/- 1.31 micrograms/ml), and hairy cell leukemia (7.04 +/- 3.69 micrograms/ml). The serum TR was significantly elevated in chronic lymphocytic leukemia (CLL; 14.17 +/- 12.29 micrograms/ml), and the serum levels reflected the clinical stage of the disease. These findings suggest that serum TR measurement may provide a useful laboratory index of disease activity in certain disorders such as CLL, whereas it most likely reflects the intensity of erythropoiesis in the remaining hematological disorders that were evaluated in this study.
 ...
PMID:Serum transferrin receptor measurements in hematologic malignancies. 216 85

Fourteen primary non-Hodgkin's malignant lymphoma (ML) of the breast observed between 1985 and 1989 were reviewed. Using the Ann Arbor staging system, 5 of these ML were at clinical stage IE, 2 at stage IIE, and only one was at clinical stage IVE (the ML involved both breasts of a young woman after her third post-partum and she died quickly), staging was not available in 6 cases. At the time of physical examination, the diagnosis of ML was not suspected. When possible, it was done or-suspected before surgery, studying fine needle aspiration cytology (4 cases) or drill biopsy (2 cases). Cytological examination was also useful to make the difference between primary large cells T ML and granulocytic sarcomas which sometimes occur before the acute myeloid leukemia and/or the blast crisis of a myeloproliferative disorder. According to the Kiel histopathological classification (updated in 1988), 78.5% of these ML were of great malignancy, more than half of them being polymorphous centroblastic B ML. Only one of them was an angiocentric pleomorphic T lymphoma of great malignancy. None of the ML of low malignancy, all of the follicular type, was a MALT (Mucosa Associated Lymphoid Tissue) ML, as described by Isaacson. Intra-epithelial lymphocytes were observed in 6 of the ML of great malignancy; but in 2 cases, they were T lymphocytes and these lympho-epithelial lesions could not be interpreted as an argument for the MALT nature of these ML. None of our cases were associated with a ML from another MALT site.
 ...
PMID:[Primary non-Hodgkin's malignant lymphoma of the breast. Anatomopathologic diagnosis of 14 cases]. 218 May 3


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>